Thank you, Dr Norrby, for your very fine summing up and for your very kind words to me and my colleagues. Summing up the total work that has been shown and spoken about over the last two days has been an onerous task. 1 congratulate you on completing it so admirably.
Chairman's Closing Remarks DrJDPrice (Glaxo Holdintgs Ltd, London, UK) Thank you, Dr Norrby, for your very fine summing up and for your very kind words to me and my colleagues. Summing up the total work that has been shown and spoken about over the last two days has been an onerous task. 1 congratulate you on completing it so admirably.
When we were first considering the clinical evaluation of cefuroxime we believed that 750 mg dosages would probably be adequate to cover the majority of infections we were starting to investigate. It is now quite evident from the collected data that, having studied a range of dosages between 500 and 1000 mg and multiples thereof, 750 mg offers perhaps the optimal dosage for most of the infections that are commonly found. When given 8 hourly the results, both bacteriologically and clinically, have been very favourable.
We must now consider our position with respect to the presentation of this compound. The data that we have, in my view, are conclusively steering us to a 750 mg vial. Multiples of this can be used for the more severe cases and in some of the more compromised patients.
The questions that have been discussed with respect to the tolerance and unwanted effects are again very reassuring. In comment in your summation, Dr Norrby, you wanted increased data. We did not, at this meeting, have a paper setting out the total information relating to tolerance that we have been able to collect from our investigators. Rather we invited the investigators to report their information individually and to discuss it so that each participant has the opportunity to see how the various aspects of the development of cefuroxime have been taking place.
However, I have in front of me a summary of the investigations which has been prepared in our Department. We know, for example, that among the many hundreds of patients treated with cefuroxime (not including the gonorrhoea patients, where large numbers have already been treated on single dose therapy), there were 32 patients with known renal impairment. Of these 32 patients, renal tolerance was assessed in 30.
In 20 cases no unwanted renal effects were observed. In the other cases, unwanted effects such as increased blood urea, decreased creatinine clearance or increased albumin, were noted, but in 7 of these the effect has been attributed to the disease process of which the patient was complaining, and in the remaining 3 it was not possible to determine whether the unwanted effects were due to the drug or to the disease.
As to patients with normal renal function, we have data on 731 of whom we are assessing 516 with the full complement of their parameters measured before, during and after therapy. In 430 of these cases, no unwanted effects were noted. We have some changes, such as white blood cells or increased plasma protein in the urine, in a total of 86 patients. However, in 56 of these the effect could be clearly demonstrated to be due to the disease, such as cystitis or urinary tract infection. Of the 30 remaining patients, there is only one where we consider, after reviewing his whole history, that there was some abnormality in the urine attributable to cefuroxime. It is therefore an extremely well tolerated drug as in the group of patients where we have been monitoring their whole internal milieu.
I would now like to close the meeting. My task at the moment is to offer thanks to the various people who have made it possible. First, 1 think we should thank Glaxo Research Ltd who produced the compound. Then, personally, I must thank the Chairmen. They are to be congratulated on the way that they kept the meeting running to time, and for participating so actively in their sessions. As to the speakers, for preparing their work, putting in their time and being here with us, we must thank them most sincerely, and also those who took the trouble to produce posters of their work because they could not be included in the programme.
But most of all I must publicly thank all those in my Department in London, from the secretaries upwards, who have helped make the various complicated arrangements that have been necessary for this Conference to work.
It is hardly fair to single out any one person in this group, but obviously if it had not been for the tireless devotion of my Conference Secretary, John Clifton, this meeting could never have taken place. I hope that the papers, the discussions and the presentations have stimulated many new ideas on research with cefuroxime. My colleagues in the medical department look forward to a continued research programme with this compound and to meeting you all again on subsequent occasions.
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